ADGM Company Profile and Key Details

ADGM has shown weak momentum, losing -7.14% over the past week and -36.65% over the past quarter, though year-to-date performance is down -16.25%. Short-term trend indicators are mixed aligned (SMA20 2.94%, SMA50 3.59%, SMA200 -18.55%). The stock’s 14-day RSI is 57.31 (neutral), while the ATR of 0.08 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -64.11% below its high and over 64.8% above its low. Average 10-day trading volume of 361.48 thousand shares is below the 3-month average of 8.11 million, indicating normal recent market interest.

Adagio Medical Holdings, Inc. has 22.21 million shares outstanding. The public float is 8.41 million shares, elevated short interest at 0.49% of float. This equals 59.55 thousand shares. The short ratio is 0.77 days. Institutional investors hold 71.34% of the float. Insiders own 1.17%. PERCEPTIVE ADVISORS LLC holds 1.34 million shares, Usen Todd has 207.32 thousand shares and Kaster Deborah has 15.00 thousand shares.

Adagio Medical Holdings, Inc. generated EPS of -$5.28 over the past year. Five-year average earnings growth is -816.44%. Analyst sentiment is bullish. Analyst rating data shows there are 1 Strong Buy ratings, 2 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $4.00 to $3.00. The high target offers 577.97% upside. The low target suggests 408.47% downside. The mean target is $3.33. This offers 464.41% upside. Adagio Medical Holdings, Inc. earnings surprise history is a mixed track record. The quarter that ended August 11, 2026, missed forecasts by 11.11%. The prior quarter beat by 6.9%. Over the last six quarters, Apple has recorded several small beats. These include 53.49% in November 12, 2025.

Adagio Medical Holdings, Inc. (NASDAQ:ADGM) closed at $0.59 USD, losing -$0.06 (-9.09%) from the previous close of $0.65. The stock is currently mid-range between its 52-week high and low $0.36 and $2.58. With a market capitalization of about $13.11 million, Adagio Medical Holdings, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~-0.19). Key stats such as the average daily volume over the past year has been around 8.28 million shares, volume is running light vs its 52-week average. Headquartered in Laguna Hills, CA, Adagio Medical Holdings, Inc. operates in the Healthcare sector and the Medical - Devices industry. Led by CEO Todd Usen, the company employs approximately 41 people and listed since August 01, 2024. Adagio Medical Holdings, Inc. is an emerging medical device firm focused on pioneering and commercializing innovative ablation technologies.

Adagio Medical Holdings, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.28. This means the shares are trading below this model’s fair value.

Adagio Medical Holdings, Inc. trades at a P/E ratio of -0.44, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of -33.45 indicating negative book value, which may reflect financial stress. The P/FCF stands at -0.86, also above market averages.

Adagio Medical Holdings, Inc. (NASDAQ:ADGM) shares are down -16.25% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Adagio Medical Holdings, Inc. trading at a premium to the broader market with a P/E of -0.44. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $3.33, suggesting 464.31% upside. Our AI forecast model points to short-term strength (16.93% over two weeks), a medium-term fall (-64.41% over three months), and a longer-term loss (-35.6% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Adagio Medical Holdings, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 16.93%, with price expected at $0.69 by September 04, 2026, within a range of $0.56 to $0.81 3-Month Outlook: Projected fall of -64.41%, reaching $0.21 by November 19, 2026, with a range of $0.16 to $0.28. 1-Year Outlook: Projected loss of -35.6%, with price at $0.38 by August 20, 2027, within a range of $0.00 to $0.00.